A-366,833

From Self-sufficiency
Jump to: navigation, search
A-366,833
240px
Systematic (IUPAC) name
5-[(1S,5R)-3,6-diazabicyclo[3.2.0]hept-6-yl]pyridine-3-carbonitrile
Identifiers
PubChem CID 9834234
Chemical data
Formula C11H12N4
Molar mass 200.239[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

A-366,833 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors selective for the α4β2 subtype, and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Ji, J.; Bunnelle, W.; Anderson, D.; Faltynek, C.; Dyhring, T.; Ahring, P.; Rueter, L.; Curzon, P.; Buckley, M. (2007). "A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo3.2.0-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models". Biochemical pharmacology. 74 (8): 1253–1262. doi:10.1016/j.bcp.2007.08.010. PMID 17854775.  edit
  2. Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.  edit